74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
DexCom Inc
Closed
SectorHealthcare
70.74 5.46
Overview
Share price change
24h
Min
66.81
Max
70.94
Income | 17M 152M |
|---|---|
Sales | 119M 1.1B |
P/E Sector Avg | 46.556 57.333 |
EPS | 0.45 |
Profit margin | 13.624 |
Employees | 10,200 |
EBITDA | 5M 242M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +49.48% upside |
Next Earnings | 1 May 2025 |
|---|
Market Cap | -8.4B 26B |
|---|---|
Previous open | 65.28 |
Previous close | 70.74 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
DexCom Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
DexCom Inc Forecast
Price Target
By TipRanks
49.48% upside
12 Months Forecast
Average 99.94 USD 49.48%
High 115 USD
Low 82 USD
Based on 19 Wall Street analysts offering 12 month price targets forDexCom Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
